In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

When Henry Conway hit his forties his BMI became dangerously high. After a lover said ‘I love your little dad bod’, he knew ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Warren Buffett changing course to invest in disruptive innovation isn’t going to happen in the New Year. What else do ...

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

US legislators from both parties agreed on a plan to keep the government funded until March. Then Elon Musk, co-head of ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.